Cite

    Pusztai, L. et al. (n.d.). 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. Journal for immunotherapy of cancer. pp. A198-A199. [Online].